These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 25114071)

  • 1. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers.
    Ivanoiu A; Dricot L; Gilis N; Grandin C; Lhommel R; Quenon L; Hanseeuw B
    J Alzheimers Dis; 2015; 43(3):835-47. PubMed ID: 25114071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild cognitive impairment: clinical and imaging profile in a memory clinic setting in India.
    Alladi S; Shailaja M; Mridula KR; Haritha CA; Kavitha N; Khan SA; Divyaraj G; Kaul S
    Dement Geriatr Cogn Disord; 2014; 37(1-2):113-24. PubMed ID: 24135787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.
    Dufouil C; Dubois B; Vellas B; Pasquier F; Blanc F; Hugon J; Hanon O; Dartigues JF; Harston S; Gabelle A; Ceccaldi M; Beauchet O; Krolak-Salmon P; David R; Rouaud O; Godefroy O; Belin C; Rouch I; Auguste N; Wallon D; Benetos A; Pariente J; Paccalin M; Moreaud O; Hommet C; Sellal F; Boutoleau-Bretonniére C; Jalenques I; Gentric A; Vandel P; Azouani C; Fillon L; Fischer C; Savarieau H; Operto G; Bertin H; Chupin M; Bouteloup V; Habert MO; Mangin JF; Chêne G;
    Alzheimers Res Ther; 2017 Aug; 9(1):67. PubMed ID: 28851447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome.
    Guo LH; Alexopoulos P; Eisele T; Wagenpfeil S; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):325-33. PubMed ID: 22932720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early alzheimer disease in patients of a memory clinic.
    Scheurich A; Muller MJ; Siessmeier T; Bartenstein P; Schmidt LG; Fellgiebel A
    Dement Geriatr Cogn Disord; 2005; 20(5):271-7. PubMed ID: 16158009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Classification of Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Integrated 18F-FDG PET and DTI Study.
    Li W; Zhao Z; Liu M; Yan S; An Y; Qiao L; Wang G; Qi Z; Lu J
    J Alzheimers Dis; 2022; 85(3):1063-1075. PubMed ID: 34897092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.
    Prestia A; Caroli A; Wade SK; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo IH; Nordberg A; Scheltens P; Frisoni GB
    Alzheimers Dement; 2015 Oct; 11(10):1191-201. PubMed ID: 25646957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.